Nls pharmaceutics to present interim top-line data for quilience(r) (mazindol er) in patients with narcolepsy at the world sleep congress in march 2022

Phase 2a trial meets enrollment target for interim analysis and is now more than 50% enrolled 21 clinical sites in the united states actively enrolling patients nearly 90% of patients completing the trial have opted into the open label extension study zurich, switzerland / accesswire / february 7, 2022 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it will present interim top-line data from its phase 2a clinical trial evaluating its lead product candidate, quilience® (mazindol er), for the treatment of narcolepsy at this year's world sleep congress (world sleep 2022), taking place in rome, italy march 11-16, 2022.
NLSP Ratings Summary
NLSP Quant Ranking